Jafron Biomedical Co.,Ltd. (SHE:300529)
China
· Delayed Price · Currency is CNY 26.40
-0.32 (-1.20%)
Apr 2, 2025, 2:45 PM CST
Jafron Biomedical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Net Income | 804.47 | 436.49 | 889.56 | 1,197 | 875.24 | 570.82 | Upgrade
|
| Depreciation & Amortization | 92.86 | 92.86 | 73.99 | 54.06 | 36.73 | 29.79 | Upgrade
|
| Other Amortization | 20.13 | 20.13 | 8.63 | 4.68 | 2.17 | 1.02 | Upgrade
|
| Loss (Gain) From Sale of Assets | -6.72 | -6.72 | -0.86 | -0.98 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 27.07 | 27.07 | 7.86 | 1.15 | 0.48 | 1.35 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | -10.51 | -28.72 | -15.19 | -34.6 | Upgrade
|
| Provision & Write-off of Bad Debts | -9.4 | -9.4 | -1.99 | 6.76 | 0.82 | 1.88 | Upgrade
|
| Other Operating Activities | -40.25 | 46.17 | 27.72 | 7.69 | -1.1 | -2.15 | Upgrade
|
| Change in Accounts Receivable | 277.22 | 277.22 | -7.9 | -110.41 | -83.41 | -34.23 | Upgrade
|
| Change in Inventory | -37.3 | -37.3 | -152.74 | -75.93 | -28.29 | -31.2 | Upgrade
|
| Change in Accounts Payable | 52.14 | 52.14 | 60.66 | 203.27 | 150.6 | 66.61 | Upgrade
|
| Change in Other Net Operating Assets | 19.1 | 19.1 | -8.59 | 8.27 | 22.35 | 17.13 | Upgrade
|
| Operating Cash Flow | 1,198 | 916.74 | 883.8 | 1,249 | 957.49 | 583.5 | Upgrade
|
| Operating Cash Flow Growth | 26.30% | 3.73% | -29.26% | 30.49% | 64.09% | 51.92% | Upgrade
|
| Capital Expenditures | -325.77 | -247.25 | -475.89 | -537.41 | -357.11 | -220.67 | Upgrade
|
| Sale of Property, Plant & Equipment | 5.47 | 12.6 | 6.91 | 0.99 | 0.81 | 0.02 | Upgrade
|
| Cash Acquisitions | - | - | -0.18 | - | - | -6.28 | Upgrade
|
| Investment in Securities | -2,043 | -15 | 163.26 | -133.8 | - | -4.79 | Upgrade
|
| Other Investing Activities | 24.46 | - | - | - | 15.19 | 34.6 | Upgrade
|
| Investing Cash Flow | -2,338 | -249.65 | -305.9 | -670.22 | -341.11 | -197.12 | Upgrade
|
| Long-Term Debt Issued | - | 762.92 | 296.32 | 998.3 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -349.47 | -6.11 | -6.02 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -131.48 | 413.45 | 290.21 | 992.28 | - | - | Upgrade
|
| Issuance of Common Stock | 123.68 | 123.81 | 67.29 | 195.09 | 72.07 | 54.15 | Upgrade
|
| Repurchase of Common Stock | -383.87 | -383.87 | -5.19 | -500.13 | -8.29 | - | Upgrade
|
| Common Dividends Paid | -338.52 | -561.79 | -729.42 | -531.02 | -377.81 | -251.01 | Upgrade
|
| Other Financing Activities | -110.44 | -43.51 | 11.19 | 8.94 | 1 | 1.41 | Upgrade
|
| Financing Cash Flow | -840.62 | -451.91 | -365.93 | 165.18 | -313.03 | -195.44 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.76 | 0.01 | -0.04 | -0 | -0.04 | -0 | Upgrade
|
| Net Cash Flow | -1,982 | 215.19 | 211.93 | 744.37 | 303.32 | 190.93 | Upgrade
|
| Free Cash Flow | 872.54 | 669.49 | 407.91 | 712 | 600.37 | 362.82 | Upgrade
|
| Free Cash Flow Growth | 10.48% | 64.13% | -42.71% | 18.59% | 65.47% | 72.32% | Upgrade
|
| Free Cash Flow Margin | 33.15% | 34.83% | 16.37% | 26.61% | 30.78% | 25.34% | Upgrade
|
| Free Cash Flow Per Share | 1.10 | 0.84 | 0.51 | 0.89 | 0.74 | 0.46 | Upgrade
|
| Cash Income Tax Paid | 427.96 | 255.53 | 441.93 | 427.62 | 297.68 | 275.48 | Upgrade
|
| Levered Free Cash Flow | 458.47 | 537.27 | 18.61 | 228.28 | 252.21 | 125.24 | Upgrade
|
| Unlevered Free Cash Flow | 497.21 | 571.23 | 41.13 | 233.85 | 252.21 | 125.24 | Upgrade
|
| Change in Net Working Capital | -107.32 | -384.54 | 136.03 | 122.35 | 55.36 | 79.84 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.